Drug Industry
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions
Lilly Collaborates with OpenAI to Develop Novel Antibiotics Against Drug-Resistant Pathogens
Lilly, OpenAI, Antibiotics, Antimicrobial Resistance, Drug-Resistant Pathogens, Generative AI, Pharmaceutical Industry
Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years
Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry
Bristol Myers Squibb to Cut Over 860 Jobs in New Jersey as Part of $1.5 Billion Savings Campaign
Bristol Myers Squibb, job cuts, New Jersey, $1.5 billion savings campaign, cost savings, pharmaceutical industry
Biotech Faces a Reckoning: The Challenges and Shifts in Cell Therapies
cell therapy, biotech, gene therapy, autoimmune diseases, manufacturing challenges, market acceptance, pharmaceutical industry
Delaware Court Ruling Allows Zantac Lawsuits to Proceed, GSK Market Cap Plummets by Over $8 Billion
Zantac lawsuits, GSK market cap, Delaware court, pharmaceutical industry, legal battles, financial impact
James Sabry Departs Roche After 14 Years, Returns to Biotech Industry
James Sabry, Roche, Genentech, Biotech, Partnering, Pharmaceutical Industry, Career Moves
Eli Lilly Invests $5.3 Billion to Boost Production of Mounjaro and Zepbound
** Eli Lilly, Mounjaro, Zepbound, Manufacturing, Investment, Diabetes, Obesity, Weight Loss, Pharmaceutical Industry
Pfizer’s Continuous Cost-Cutting: A $4B Savings Drive Extended to 2027
Pfizer, cost-cutting, savings drive, 2027, pharmaceutical industry, restructuring, efficiency, profitability.
Exscientia Streamlines Operations, Prioritizes AI-Driven Drug Discovery
Exscientia, AI-generated pipeline, drug discovery, staff reduction, operational efficiency, biotechnology, pharmaceutical industry